Patents by Inventor Petrus Josephus Marie Rottier

Petrus Josephus Marie Rottier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9796996
    Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: October 24, 2017
    Assignee: UNIVERSITEIT UTRECHT HOLDING B.V.
    Inventors: Petrus Josephus Marie Rottier, Hui-wen Chang, Herman F. Egberink
  • Publication number: 20170266274
    Abstract: The invention relates to a mutant Porcine Epizootic Diarrhea Virus (PEDVdN), to methods of producing said PEDVdN, and to compositions comprising the PEDVdN. The invention further relates to methods of stimulating an immune response in a pig comprising administering the PEDVdN, to vaccines comprising the PEDVdN, and to methods for preventing or ameliorating porcine epizootic diarrhoea in a pig.
    Type: Application
    Filed: August 10, 2015
    Publication date: September 21, 2017
    Applicant: Universiteit Utrecht Holding B.V.
    Inventors: Berend Jan Bosch, Petrus Josephus Marie Rottier
  • Patent number: 9585953
    Abstract: The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumor origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: March 7, 2017
    Assignee: MUCOSIS B.V.
    Inventors: Cornelis Johannes Leenhouts, Bert Jan Haijema, Maarten Leonardus van Roosmalen, Petrus Josephus Marie Rottier, Cornelis Alexander Maria de Haan, Berend Jan Bosch
  • Patent number: 9060975
    Abstract: Heat-stable oligomeric recombinant polypeptides, presenting at least one antigenic epitope of the pre-fusion Respiratory Syncytial Virus (RSV) F protein, comprising the RSV F protein ectodomain, functionally deleted in the HRB region, transmembrane and cytoplasmic domains replaced with a heterologous trimerization domain, and absent two functional multibasic furin cleavage sites, are useful as antigenic components in immunogenic compositions useful in methods of inducing an immune response and vaccinate against RSV infections.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 23, 2015
    Assignee: Mucosis BV
    Inventors: Cornelis Alexander Maria de Haan, Petrus Josephus Marie Rottier, Bert Jan Haijema
  • Publication number: 20140271696
    Abstract: Heat-stable oligomeric recombinant polypeptides, presenting at least one antigenic epitope of the pre-fusion Respiratory Syncytial Virus (RSV) F protein, comprising the RSV F protein ectodomain, functionally deleted in the HRB region, transmembrane and cytoplasmic domains replaced with a heterologous trimerization domain, and absent two functional multibasic furin cleavage sites, are useful as antigenic components in immunogenic compositions useful in methods of inducing an immune response and vaccinate against RSV infections.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: MUCOSIS BV
    Inventors: Cornelis Alexander Maria de Haan, Petrus Josephus Marie Rottier, Bert Jan Haijema
  • Publication number: 20140093532
    Abstract: The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumour origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient.
    Type: Application
    Filed: March 22, 2012
    Publication date: April 3, 2014
    Applicant: MUCOSIS B.V.
    Inventors: Cornelis Johannes Leenhouts, Bert Jan Haijema, Maarten Leonardus Van Roosmalen, Petrus Josephus Marie Rottier, Cornelis Alexander Maria De Haan, Berend Jan Bosch
  • Publication number: 20130071833
    Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.
    Type: Application
    Filed: January 18, 2011
    Publication date: March 21, 2013
    Applicant: Universiteit Utrecht Holding B.V.
    Inventors: Petrus Josephus Marie Rottier, Hui-Wen Chang, Herman F. Egberink
  • Publication number: 20130034578
    Abstract: The invention relates to immunogenic compositions comprising recombinant multimeric influenza proteins or parts thereof fused to a streptavidin affinity tag, preferably recombinant trimeric influenza virus hemagglutinin and/or recombinant tetrameric influenza virus neuraminidase, or vectors comprising nucleic acid sequences encoding such influenza proteins. The inventions further relate to methods for the preparation of such immunogenic compositions and uses thereof and methods for eliciting an immune response in an individual.
    Type: Application
    Filed: April 8, 2011
    Publication date: February 7, 2013
    Inventors: Petrus Josephus Marie Rottier, Berend Jan Bosch, Cornelis Alexander Maria De Haan
  • Patent number: 7556957
    Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines derived therefrom. The invention provides replicative coronaviruses and virus-like particles (VLPs) from which large parts of their genome are (at least functionally) deleted without abolishing their replicative capacities. The deletion preferably results in at least a functional deletion in that the corresponding gene is not or is only partly expressed wherein the resulting gene product is dysfunctional or at least functionally distinct from a corresponding wild-type gene product.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: July 7, 2009
    Assignees: Stichting voor de Technische Wetenschappen, Universiteit Utrecht
    Inventors: Petrus Josephus Marie Rottier, Cornelis Alexander Maria De Haan, Bert Jan Haijema
  • Publication number: 20040071709
    Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutics, and vaccines derived thereof. Methods are shown for at least in part inhibiting anti-parallel coiled coil formation of a coronavirus spike protein wherein the methods include decreasing the contact between heptad repeat regions of the protein. The invention provides a peptide including a heptad repeat region of a corona viral spike protein and/or a functional fragment and/or an equivalent thereof. The invention also provides antibodies and inhibiting compounds.
    Type: Application
    Filed: April 14, 2003
    Publication date: April 15, 2004
    Inventors: Petrus Josephus Marie Rottier, Berend-Jan Bosch
  • Patent number: RE47471
    Abstract: Heat-stable oligomeric recombinant polypeptides, presenting at least one antigenic epitope of the pre-fusion Respiratory Syncytial Virus (RSV) F protein, comprising the RSV F protein ectodomain, functionally deleted in the HRB region, transmembrane and cytoplasmic domains replaced with a heterologous trimerization domain, and absent two functional multibasic furin cleavage sites, are useful as antigenic components in immunogenic compositions useful in methods of inducing an immune response and vaccinate against RSV infections.
    Type: Grant
    Filed: March 26, 2016
    Date of Patent: July 2, 2019
    Assignee: Mucosis B.V.
    Inventors: Cornelis Alexander Maria de Haan, Petrus Josephus Marie Rottier, Bert Jan Haijema